Navigation Links
Xenomics Announces Issuance of a US Patent That Covers Use of Transrenal Nucleic Acid Technology for Infectious Disease Diagnostics and Monitoring
Date:11/14/2007

NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- Xenomics, Inc. (the "Company") (OTC Pink Sheets: XNOM; FWB: XE7) a developer of next-generation medical DNA diagnostic technologies, announced today issuance of its US patent "Methods for detection of nucleic acid sequences in urine," RE39,920 that covers use of its proprietary transrenal nucleic acid technology in the area of infectious disease diagnostics and monitoring.

Transrenal nucleic acids (Tr-DNA and Tr-RNA) are fragments of DNA and RNA from cells dying throughout the body that cross the kidney barrier from blood to urine and can be used for genetic analysis. Xenomics' previous patents covered applications of the Tr-NA technology for prenatal genetic testing, tumor diagnostics and monitoring, and detection of rejection episodes after organ transplantation. The new patent covers diagnosis and monitoring of infectious diseases, the most rapidly growing area of molecular diagnostics.

The molecular diagnostic segments in general are projected to outperform the overall diagnostics market, growing from $13.8 billion in 2005 to $22.7 billion in 2010. Currently, the largest market application segment for molecular diagnostics is infectious disease testing.

Xenomics' scientists have detected in urine DNA and RNA fragments of different pathogens, including viruses, bacteria and parasites, that infected organs and tissues located outside of urinary system. Pulmonary tuberculosis, malaria, leishmania, HIV, H. pylori-induced ulcers of stomach and duodenum, cervical cancer caused by HPV (Human Papilloma Virus) are only some examples of diseases where the Tr-NA technology can be applied.

"The issuance of this patent significantly enhances our patent portfolio," commented Gianluigi Longinotti-Buitoni, Executive Chairman of Xenomics. "It is especially important for us now when several clinical tests for diagnosis of infectious diseases as well as for detecting tumors caused by viral infections are under development at Xenomics."

About Xenomics, Inc.

Xenomics is a molecular diagnostics company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a European patent for the Company's prenatal testing applications, and numerous pending patent applications. For more investor-specific information, including daily and historical Company stock quote data, recent news releases and an Investor Fact Sheet, please visit http://www.xenomics.com. Xenomics is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006 and its other periodic reports, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.

CONTACT:

Samuil Umansky

Xenomics, Inc.

+1-732-438-8290 ext. 201

sumansky@xenomics.com


'/>"/>
SOURCE Xenomics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Cardiology devices ... the projected period The Cardiology Devices segment is ... than US$ 15 Mn in 2018 over 2017. By the ... a market valuation close to US$ 700 Mn, expanding at ... Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical ... devices are tubes used to remove excess liquid and ... serum, pus, urine, bile or lymph. Surgical drains are ... surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic ... prophylactic post-surgery to prevent accumulation of fluid e.g. blood ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance against ... related to Zika virus during pregnancy, as well as other prenatal exposures like ... , The Teratology Society is an international and multidisciplinary group ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing enhancements ... their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered nurses ... as 16 months and for as little as $14,528. These changes will enable nurses ...
(Date:4/24/2017)... ... 2017 , ... The Santana Telehealth Project was honored with the 2017 ATA ... Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am proud ... lives of the poor and underserved in other parts of the world,” said Jonathan ...
Breaking Medicine News(10 mins):